Nicotine Dependence
📧 Sign up to get email alerts when something new happens for Nicotine Dependence.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Neural Correlates of Neurofeedback Training [NA]
An update on a clinical trial investigating neural correlates of neurofeedback training, involving nicotine dependence, depression, and PTSD…
-
CLINICAL_TRIALS withdrawal · 2017-05-22Clinical Trial Update: Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers [Phase 1, Phase 2]
Clinical trial update on atomoxetine's effects on nicotine response and stress response in smokers, involving Phase 1 and Phase 2 studies, w…
-
FDA approval · 2017-05-04FDA Approved: APLENZIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental NDA for APLENZIN (bupropion hydrobromide) from Bausch Health US, LLC. The approval involves a supplemental submi…
-
CLINICAL_TRIALS withdrawal · 2017-05-01Clinical Trial Update: D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking) [Phase 2]
A Phase 2 trial evaluating D-Cycloserine augmentation of exposure-based CBT for smoking cessation was withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-04-21Clinical Trial Update: Wisconsin Tobacco Quit Line Medicaid Incentive Evaluation [NA]
Completed evaluation of Medicaid incentives for a Wisconsin tobacco quit line; results were posted in 2017.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-04-20Clinical Trial Update: Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction [Phase 2]
Phase 2 screening study evaluating gemfibrozil as a treatment for nicotine dependence has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-04-19Clinical Trial Update: Sensitivity to Intravenous Nicotine: Genetic Moderators [Phase 1]
A Phase 1 clinical trial update from Yale University examining how genetic factors modulate sensitivity to intravenous nicotine in individua…
-
CLINICAL_TRIALS trial_result · 2017-04-18Clinical Trial Update: Effectiveness of Bupropion for Treating Nicotine Dependence in Young People [Phase 2]
Phase 2 clinical trial results evaluate the effectiveness of bupropion for nicotine dependence in young people; the study is completed with …
-
FDA approval · 2017-04-17FDA Approved: RUGBY NICOTINE POLACRILEX GUM, ORIGINAL FLAVOR — Supplemental Application (Rugby Laboratories)
The FDA approved a supplemental application for Rugby Nicotine Polacrilex Gum, Original Flavor (nicotine polacrilex gum) produced by Rugby L…
-
FDA approval · 2017-04-17FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Dr. Reddys Laboratories Inc.)
The FDA approved a supplemental application for Bupropion hydrochloride SR from Dr. Reddy's Laboratories Inc., enabling marketing of this ge…
-
FDA approval · 2017-04-17FDA Approved: GOOD NEIGHBOR PHARMACY NICOTINE — Supplemental Application (Amerisource Bergen)
The FDA approved a supplemental application for GOOD NEIGHBOR PHARMACY NICOTINE (nicotine polacrilex), expanding its approval for this nicot…
-
FDA approval · 2017-04-14FDA Approved: NICOTINE POLACRILEX MINT — Supplemental Application (Walgreens)
FDA approved Walgreens' supplemental application to market NICOTINE POLACRILEX MINT (nicotine polacrilex), a mint-flavored nicotine replacem…
-
FDA label_change · 2017-04-14FDA Approved: RUGBY NICOTINE POLACRILEX GUM, COATED MINT FLAVOR — Supplemental Application (Rugby Laboratories)
FDA approved a supplemental application to add a coated mint flavor to Rugby Nicotine Polacrilex Gum, a nicotine replacement therapy for aid…
-
FDA approval · 2017-04-12FDA Approved: RUGBY NICOTINE POLACRILEX GUM, ORIGINAL FLAVOR — Supplemental Application (Rugby Laboratories)
FDA approved a supplemental application for Rugby Nicotine Polacrilex Gum, Original Flavor, confirming its continued availability as an over…
-
FDA approval · 2017-04-12FDA Approved: NICOTINE — Supplemental Application (P & L Development, LLC)
The FDA approved a supplemental application for nicotine polacrilex (NICOTINE) gum from P & L Development, LLC.
-
CLINICAL_TRIALS withdrawal · 2017-04-12Clinical Trial Update: Trial of Computerized MET for Adolescent Substance Use [Phase 1]
A Phase 1 trial of a computerized Motivational Enhancement Therapy (MET) for adolescent substance use has been withdrawn.
-
FDA approval · 2017-04-11FDA Approved: NICOTINE POLACRILEX MINT — Supplemental Application (Walgreens)
FDA approved a supplemental application for Walgreens' Nicotine Polacrilex Mint, confirming continued approval of this generic nicotine repl…
-
FDA approval · 2017-04-11FDA Approved: NICOTINE — Supplemental Application (P & L Development, LLC)
FDA approved a supplemental application for NICOTINE POLACRILEX, a nicotine replacement therapy, from P & L Development, LLC.
-
CLINICAL_TRIALS research · 2017-04-10Clinical Trial Update: Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction [Phase 1]
Phase 1 study evaluating whether transdermal nicotine replacement therapy (nicotine patch) induces metabolic changes in smokers; the trial i…
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Duration of Follow-Up Counselling on Smoking Cessation Outcomes [NA]
A completed study from National University Hospital, Singapore, examining how the duration of follow-up counselling influences smoking cessa…
-
CLINICAL_TRIALS trial_result · 2017-04-06Clinical Trial Update: A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence [Phase 2]
Phase 2 safety and cognitive function study of encenicline (EVP-6124) versus placebo in nicotine dependence and smoking cessation was termin…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Treatment of Nicotine Dependence and Acute Depression [Phase 4]
Phase 4 clinical trial investigating treatment for nicotine dependence and acute depression completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-03-28Clinical Trial Update: Treatment of Smoking Lapses and Relapses [Phase 4]
Phase 4 clinical trial update from the University of Vermont on treating smoking lapses and relapses, with the study status completed and re…
-
CLINICAL_TRIALS trial_result · 2017-03-23Clinical Trial Update: N-Acetylcysteine and Smoking Reduction [Phase 2]
A Phase 2 clinical trial evaluating N-acetylcysteine for smoking reduction in nicotine dependence has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking. [Phase 2]
A Phase 2 study evaluating the nicotine vaccine NIC002 in smokers motivated to quit has completed, assessing efficacy, safety, tolerability …